EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma

Lea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, Jessica C Hassel, Michael Erdmann, Andrea Forschner, Douglas B Johnson, Renáta Váraljai, Georg Lodde, Jan Malte Placke, Frederik Krefting, Anne Zaremba und 11 weitere

European Journal of Cancer · 2024

DOI: 10.1016/j.ejca.2024.113976 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Lea Jessica Albrecht und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), E…. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Effective treatment options are limited for patients with advanced melanoma who have progressed on immune checkpoint inhibitors (ICI) and targeted therapies (TT). Preclinical models support the combination of ICI with TT; however, clinical trials evaluating the efficacy of triplet combinations in first-line setting showed limited advantage compared to TT only. METHODS: We conducted a retrospective, multicenter study, that included patients with advanced melanoma who were treated with BRAF/MEK inhibitors in combination with an anti-PD-(L)1 antibody (triplet therapy) after failure of at least one anti-PD-(L)1-based therapy and one TT in seven major melanoma centers between February 2016 and July 2022. RESULTS: A total of 48 patients were included, of which 32 patients, 66.7% had brain metastases, 37 patients (77.1%) had three or more metastatic organs and 21 patients (43.8%) had three or more treatment lines. The median follow-up time was 31.4 months (IQR, 22.27-40.45 months). The treatment with triplet therapy resulted in an ORR of 35.4% (n = 17) and a DCR of 47.9% (n = 23). The median DOR was 5.9 months (range, 3.39-14.27 months). Patients treated with BRAF/MEK inhibitors as the last treatment line showed a slightly lower ORR (29.6%) compared to patients who received ICI or chemotherapy last (ORR: 42.9%). Grade 3-4 treatment-related adverse events occurred in 25% of patients (n = 12), with seven patients (14.6%) requiring discontinuation of treatment with both or either drug. CONCLUSIONS: Triplet therapy has shown activity in heavily pretreated patients with advanced melanoma and may represent a potential treatment regimen after failure of ICI and TT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsHumansImmune Checkpoint InhibitorsProto-Oncogene Proteins B-rafRetrospective StudiesAntineoplastic Combined Chemotherapy ProtocolsMitogen-Activated Protein Kinase KinasesProtein Kinase InhibitorsMutation

Stichwörter der Autor:innen

Advanced melanomaAnti-PD-(L)1 plus BRAF/MEK inhibitorsAnti-PD-1 resistanceBRAF V600 mutationTriplet combinationTriplet therapy

Substanzen

Immune Checkpoint InhibitorsProto-Oncogene Proteins B-rafMitogen-Activated Protein Kinase KinasesProtein Kinase InhibitorsBRAF protein, human

Autor:innen und Institutionen

  • Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.
  • Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
  • Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
  • Department of Dermatology and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
  • Department of Dermatology, Uniklinikum Erlangen and the Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), Erlangen, Germany.
  • Department of Dermatology, University Hospital Tuebingen, Tuebingen, Germany.

Zitieren

APA

Albrecht, L. J., Dimitriou, F., Grover, P., Hassel, J. C., Erdmann, M., Forschner, A., Johnson, D. B., Váraljai, R., Lodde, G., Placke, J. M., Krefting, F., Zaremba, A., Ugurel, S., Roesch, A., Schulz, C., Berking, C., Pöttgen, C., Menzies, A. M., Long, G. V., …, & Zimmer, L. (2024). Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.113976

Vancouver

Albrecht LJ, Dimitriou F, Grover P, Hassel JC, Erdmann M, Forschner A, et al. Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.113976

BibTeX
@article{Albrecht2024,
  author = {Albrecht, Lea Jessica and Dimitriou, Florentia and Grover, Piyush and Hassel, Jessica C and Erdmann, Michael and Forschner, Andrea and Johnson, Douglas B and Váraljai, Renáta and Lodde, Georg and Placke, Jan Malte and Krefting, Frederik and Zaremba, Anne and Ugurel, Selma and Roesch, Alexander and Schulz, Carsten and Berking, Carola and Pöttgen, Christoph and Menzies, Alexander M and Long, Georgina V and Dummer, Reinhard and Livingstone, Elisabeth and Schadendorf, Dirk and Zimmer, Lisa},
  title = {Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma},
  journal = {European Journal of Cancer},
  year = {2024},
  doi = {10.1016/j.ejca.2024.113976}
}
Kostenlos starten →